Azora Therapeutics, Inc.

US$3.76As of Sun 8 Nov 2026, 12:00 UTC

NASDAQ:AZRHealthcare

Country USA

PE (Fwd) —

TSR 8Y CAGR (53.32%)

Div yield —

ROE —

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (57.03%)

Mkt cap US$9.873M

ROIC —

SE Grade™

—

Value

—

Quality

—

Moat

—

1Y Price

Reference

$7.65

—

103.51%

—

Buy 1|2|0|0|0

TTM

FYE 31 Dec USD

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

◌—

Revenue$M

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(64.06)

FCF yield (avg)%

—

(53.14)

(93.32)

(94.03)

(102.44)

—

(93.67)

—

FCF margin%

—

0.193

FCF / Net incomex

—

0.879

1.329

0.525

0.814

—

0.846

—

ROIC%

—

(1865.33)

(1052.66)

—

(1459.00)

—

Return on equity%

—

(388.57)

(139.22)

(323.80)

(170.73)

—

(247.27)

—

(198.70)

Return on assets%

—

(222.08)

(108.16)

(261.65)

(119.54)

—

(170.81)

—

(12.51)

EPS$

—

(317.81)

(89.91)

(68.01)

(11.93)

(4.94)

—

EPS growth%

—

71.71

24.36

82.46

58.59

71.71

—

(8.30)

Bookvalue per sh$

—

81.79

71.66

20.96

7.89

(57.40)

(54.13%)

—

(2.41)

FCF per share$

—

(279.23)

(119.45)

(35.67)

(9.71)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

0.669

Shares (diluted)M

—

0.040

0.057

0.194

0.669

◌0.669

155.56%

—

Buyback yield%

—

(42.25)

(240.54)

(244.55)

◌—

(240.54)

—

D/E ratiox

—

0.063

—

0.063

—

(3.367)

Enterprise value$M

—

17.26

4.467

3.611

0.457

(3.367)

(70.20%)

—

LT debt$M

—

Peers (US$10.50M)

Cap (US$)

Vyome Holdings, Inc.

11.09M

—

Palatin Technologies…

10.40M

—

SeaStar Medical…

9.890M

—

Advicenne S.A.

10.29M

213.1x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

—

Own earn%

—

Sh yield%

—

(240.54)

Owners

Insiders/Inst%

48.57

—

Short interest%

25.86

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

3/3

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology.

Revenue by segment

No breakdown available

Asset mix

Trend

Cash and investments

88.13%

Other

11.87%

Reinvestment returns

No breakdown available